The Phase Ⅲ Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,200
- 试验地点
- 1
- 主要终点
- To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated)
研究概览
简要总结
The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative .
详细描述
Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative. HA contents 15μg/0.5ml per dose includ H1N1、H3N2 and B.
Inactivated Split Influenza Vaccine was manufactured by Sanofi Pasteur HA contents 15μg/0.5ml per dose includ H1N1、H3N2 and B.
This is a randomized, blind phase 3 clinical trial. Total 1200 adults (above ages 36 months ) were selected, randomized to two groups [Influenza Virus Vaccine (Split Virion, Inactivated) and Inactivated Split Influenza Vaccine , each group n=600], adults in each group will be vaccinated with one dose of either Influenza Virus Vaccine (Split Virion, Inactivated) or Sanof IVV respectively.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 36 Months 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females, age above 36 months ;
- •Adults, parent(s) or guardians are able to understand and sign informed consent for participation;
- •Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions;
- •Infants no vaccinated with influenza or other preventive biologicals in recent 7 days;
- •Axillary temperature ≤37℃.
排除标准
- •Have medical record of participants or their family on allergy and egg, convulsion, falling sickness, encephalopathy and psychopathy;
- •Low platelet or bleeding disorder do not allow vaccination into the muscle;
- •Have damaged or lower immunological function;
- •Received blood, plasma or immunoglobulin treatment since birth;
- •Have inborn abnormality, develop obstacles or clinical diagnostic serious chronic ( Down Syndrome, diabetes, sickle cell anemia or neural Guillain-Barre Syndrome );
- •Have or be doubtful of following diseases: respiratory system diseases, acute infection or active chronic, cardiovascular diseases, liver and kidney diseases, skin diseases, HIV.
结局指标
主要结局
To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated)
时间窗: six months
次要结局
未报告次要终点